Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical, Companies, Therapies, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan

DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight highlights that the Nucleic Acid and Gene Therapies pipeline for Neuromuscular Disorders includes over 25 major companies actively working on more than 30 investigational therapies.

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Overview:

Lung cancer continues to be one of the top causes of cancer-related deaths globally and is generally associated with a poor prognosis. The introduction of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand PD-L1 has significantly changed the treatment landscape for non-small cell lung cancer (NSCLC). Blocking the PD-1/PD-L1 pathway has demonstrated strong therapeutic benefits and improved survival outcomes in both preclinical and clinical studies for patients with locally advanced or metastatic NSCLC.

PD-1 is a type I transmembrane protein found on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but have different expression patterns. PD-L1 is expressed on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Both PD-1 and its ligands comprise a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.

Binding of PD-1 to PD-L1 or PD-L2 triggers phosphorylation of two intracellular tyrosine residues, which recruits the phosphatases SHP-1 and SHP-2. These phosphatases interact with PD-1's ITIM and ITSM motifs, ultimately inhibiting antigen receptor signaling. While this PD-1/ligand interaction suppresses effector T-cell function, the binding of B7-1/B7-2 to CD28 stimulates T-cell proliferation.

Request for a detailed insights report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline insights [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapeutics Market.

Key Takeaways from the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Report

*
DelveInsight's report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders highlights an active pipeline, with over 25 companies developing more than 30 investigational therapies for these conditions.

*
Key players in this space include Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others, all working to advance new treatment options and improve the therapeutic landscape. Promising pipeline candidates in various stages of development include Zimberelimab, PM8002, RPH075, among others.

*
Recent regulatory developments in the broader NSCLC treatment landscape include: In August 2024, the FDA approved AstraZeneca's durvalumab for adult NSCLC patients post-surgery, extending its use beyond advanced cases where surgery is not feasible. Additionally, in January 2023, pembrolizumab received FDA approval as an adjuvant therapy following resection and platinum-based chemotherapy for patients with stage IB (T2a greater than or equal to 4 cm), II, or IIIA NSCLC.

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nucleic Acid and Gene Therapies in Neuromuscular Disorders treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Nucleic Acid and Gene Therapies in Neuromuscular Disorders market.

Download our free sample page report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline insights [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]r [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr]

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Emerging Drugs

*
Zimberelimab: Arcus Biosciences

*
PM8002: Biotheus

*
RPH075: R-Pharm

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Companies

Over 25 leading companies are actively working on therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC), with Arcus Biosciences having drug candidates in the most advanced stage, currently in Phase III trials.

DelveInsight's report covers around 30+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapies and Key Companies: Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical Trials and advancements [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Therapeutic Assessment

- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Product Type

- Nucleic Acid and Gene Therapies in Neuromuscular Disorders By Stage

- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Route of Administration

- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Molecule Type

Download Nucleic Acid and Gene Therapies in Neuromuscular Disorders Sample report to know in detail about the Nucleic Acid and Gene Therapies in Neuromuscular Disorders treatment market @ Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapeutic Assessment [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Current Treatment Patterns

4. Nucleic Acid and Gene Therapies in Neuromuscular Disorders - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Late-Stage Products (Phase-III)

7. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Discontinued Products

13. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Product Profiles

14. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Key Companies

15. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Key Products

16. Dormant and Discontinued Products

17. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Unmet Needs

18. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Future Perspectives

19. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Analyst Review

20. Appendix

21. Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-clinical-companies-therapies-pipeline-arcus-biosciences-akeso-biopharma-biotheus-glaxosmithkline-astrazeneca-pfizer-shandong-boan]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.